{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:21:36Z","timestamp":1783038096832,"version":"3.54.6"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"crossref","award":["31897"],"award-info":[{"award-number":["31897"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-44050-1","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T17:05:39Z","timestamp":1777741539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In silico prediction, molecular docking, and dynamics analysis of steroidal alkaloids from the genus Fritillaria: implications for designing novel antiparkinsonian therapeutic strategies"],"prefix":"10.1038","volume":"16","author":[{"given":"Mohammad Ali","family":"Farboodniay Jahromi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sadeghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melika","family":"Movahedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Poustforoosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Hassan","family":"Seradj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Emami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"6","key":"44050_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong, M. J. & Okun, M. S. Diagnosis and treatment of Parkinson disease: A review. Jama 323(6), 548\u2013560 (2020).","journal-title":"Jama"},{"issue":"5","key":"44050_CR2","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.neuro.2010.04.007","volume":"31","author":"JM Vance","year":"2010","unstructured":"Vance, J. M., Ali, S., Bradley, W. G., Singer, C. & Di Monte, D. A. Gene\u2013environment interactions in Parkinson\u2019s disease and other forms of parkinsonism. Neurotoxicology 31(5), 598\u2013602 (2010).","journal-title":"Neurotoxicology"},{"issue":"6","key":"44050_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00702-023-02730-6","volume":"131","author":"M Naoi","year":"2024","unstructured":"Naoi, M., Maruyama, W., Shamoto-Nagai, M. & Riederer, P. Toxic interactions between dopamine, \u03b1-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson\u2019s disease. J. Neural Transm. 131(6), 639\u2013661 (2024).","journal-title":"J. Neural Transm."},{"key":"44050_CR4","doi-asserted-by":"publisher","first-page":"1617106","DOI":"10.3389\/fnagi.2025.1617106","volume":"17","author":"SA Chaudhary","year":"2025","unstructured":"Chaudhary, S. A., Chaudhary, S. & Rawat, S. Understanding Parkinson\u2019s disease: Current trends and its multifaceted complications. Front. Aging Neurosci. 17, 1617106 (2025).","journal-title":"Front. Aging Neurosci."},{"issue":"14","key":"44050_CR5","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1001\/jama.2020.1224","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong, M. J. & Okun, M. S. Choosing a Parkinson disease treatment. Jama 323(14), 1420 (2020).","journal-title":"Jama"},{"issue":"6","key":"44050_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41582-020-0344-4","volume":"16","author":"E-K Tan","year":"2020","unstructured":"Tan, E-K. et al. Parkinson disease and the immune system\u2014Associations, mechanisms and therapeutics. Nat. Reviews Neurol. 16(6), 303\u2013318 (2020).","journal-title":"Nat. Reviews Neurol."},{"issue":"2","key":"44050_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41583-019-0257-7","volume":"21","author":"M Parmar","year":"2020","unstructured":"Parmar, M., Grealish, S. & Henchcliffe, C. The future of stem cell therapies for Parkinson disease. Nat. Rev. Neurosci. 21(2), 103\u2013115 (2020).","journal-title":"Nat. Rev. Neurosci."},{"issue":"29","key":"44050_CR8","doi-asserted-by":"publisher","first-page":"6045","DOI":"10.2174\/0929867328666210203204710","volume":"28","author":"Z \u00d6zdemir","year":"2021","unstructured":"\u00d6zdemir, Z., Alag\u00f6z, M. A., Bah\u00e7ecio\u011flu, \u00d6. F. & G\u00f6k, S. Monoamine oxidase-B (MAO-B) inhibitors in the treatment of Alzheimer\u2019s and Parkinson\u2019s disease. Curr. Med. Chem. 28(29), 6045\u20136065 (2021).","journal-title":"Curr. Med. Chem."},{"issue":"22","key":"44050_CR9","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.4155\/fmc-2022-0167","volume":"14","author":"S Dawbaa","year":"2022","unstructured":"Dawbaa, S., Evren, A. E., Sa\u011flik, B. N., Gundogdu-Karaburun, N. & Karaburun, A. C. Biological activity evaluation of novel monoamine oxidase inhibitory compounds targeting Parkinson disease. Future Med. Chem. 14(22), 1663\u20131679 (2022).","journal-title":"Future Med. Chem."},{"issue":"2","key":"44050_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3233\/JPD-212976","volume":"12","author":"Y-Y Tan","year":"2022","unstructured":"Tan, Y-Y., Jenner, P. & Chen, S-D. Monoamine oxidase-B inhibitors for the treatment of Parkinson\u2019s disease: Past, present, and future. J. Parkinson\u2019s disease. 12(2), 477\u2013493 (2022).","journal-title":"J. Parkinson\u2019s disease"},{"issue":"35","key":"44050_CR11","first-page":"7479","volume":"41","author":"Y Nakamura","year":"2021","unstructured":"Nakamura, Y. et al. Monoamine oxidase-B inhibition facilitates \u03b1-synuclein secretion in vitro and delays its aggregation in rAAV-based rat models of Parkinson\u2019s disease. J. Neurosci. 41(35), 7479\u20137491 (2021).","journal-title":"J. Neurosci."},{"issue":"5","key":"44050_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jsbmb.2004.08.003","volume":"92","author":"A Khalid","year":"2004","unstructured":"Khalid, A., Ghayur, M. N., Feroz, F., Gilani, A. & Choudhary, M. I. Cholinesterase inhibitory and spasmolytic potential of steroidal alkaloids. J. Steroid Biochem. Mol. Biol. 92(5), 477\u2013484 (2004).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"3","key":"44050_CR13","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s00210-024-03502-z","volume":"398","author":"P Kumar","year":"2025","unstructured":"Kumar, P., Kumar, V., Sharma, S., Sharma, R. & Warghat, A. R. Fritillaria steroidal alkaloids and their multi-target therapeutic mechanisms: Insights from network pharmacology. Naunyn. Schmiedebergs Arch. Pharmacol. 398(3), 2209\u20132228 (2025).","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"key":"44050_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11010-025-05258-3","volume":"480","author":"BK Utpal","year":"2025","unstructured":"Utpal, B. K. et al. Alkaloids as neuroprotectors: Targeting signaling pathways in neurodegenerative diseases. Mol. Cell. Biochem. 480, 1\u201326 (2025).","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"44050_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s13659-022-00345-0","volume":"12","author":"M-L Xiang","year":"2022","unstructured":"Xiang, M-L. et al. Chemistry and bioactivities of natural steroidal alkaloids. Nat. Prod. Bioprospect. 12(1), 23 (2022).","journal-title":"Nat. Prod. Bioprospect."},{"issue":"1","key":"44050_CR16","doi-asserted-by":"publisher","first-page":"13398","DOI":"10.1038\/s41598-023-40160-2","volume":"13","author":"PC Agu","year":"2023","unstructured":"Agu, P. C. et al. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci. Rep. 13(1), 13398 (2023).","journal-title":"Sci. Rep."},{"issue":"1","key":"44050_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13020-021-00450-1","volume":"16","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Natural drug sources for respiratory diseases from Fritillaria: Chemical and biological analyses. Chin. Med. 16(1), 40 (2021).","journal-title":"Chin. Med."},{"key":"44050_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ejmech.2017.06.007","volume":"137","author":"Y-M Liu","year":"2017","unstructured":"Liu, Y-M. et al. Isosteroidal alkaloids as potent dual-binding site inhibitors of both acetylcholinesterase and butyrylcholinesterase from the bulbs of Fritillaria walujewii. Eur. J. Med. Chem. 137, 280\u2013291 (2017).","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"44050_CR19","doi-asserted-by":"publisher","first-page":"29179","DOI":"10.3390\/ijms161226148","volume":"16","author":"M Hofmann-Apitius","year":"2015","unstructured":"Hofmann-Apitius, M. et al. Bioinformatics mining and modeling methods for the identification of disease mechanisms in neurodegenerative disorders. Int. J. Mol. Sci. 16(12), 29179\u201329206 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"44050_CR20","doi-asserted-by":"crossref","unstructured":"Bhat, B. A., Mir, W. R., Alkhanani, M., Almilaibary, A. & Mir, M. A. Integrated study of HR-LC\/MS and network pharmacology to identify breast cancer-related molecular targets of Fritillaria cirrhosa D. Don active constituents in combination with molecular dynamic simulation and experimental evaluation (2023).","DOI":"10.21203\/rs.3.rs-2448581\/v1"},{"key":"44050_CR21","doi-asserted-by":"publisher","first-page":"985935","DOI":"10.3389\/fphar.2022.985935","volume":"13","author":"F Wu","year":"2022","unstructured":"Wu, F., Tian, M., Sun, Y., Wu, C. & Liu, X. Efficacy, chemical composition, and pharmacological effects of herbal drugs derived from Fritillaria cirrhosa D. Don and Fritillaria thunbergii Miq. Front. Pharmacol. 13, 985935 (2022).","journal-title":"Front. Pharmacol."},{"key":"44050_CR22","doi-asserted-by":"publisher","first-page":"106246","DOI":"10.1016\/j.fitote.2024.106246","volume":"179","author":"D-X Lu","year":"2024","unstructured":"Lu, D-X. et al. Three undescribed isosteroidal alkaloids from the bulbs of Fritillaria ussuriensis maxim: Anti-inflammatory activities, docking studies and molecular dynamic. Fitoterapia 179, 106246 (2024).","journal-title":"Fitoterapia"},{"issue":"8","key":"44050_CR23","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1248\/cpb.50.1013","volume":"50","author":"MN Akhtar","year":"2002","unstructured":"Akhtar, M. N. et al. New steroidal alkaloids from Fritillaria imperialis and their cholinesterase inhibiting activities. Chem. Pharm. Bull. 50(8), 1013\u20131016 (2002).","journal-title":"Chem. Pharm. Bull."},{"key":"44050_CR24","doi-asserted-by":"publisher","first-page":"106279","DOI":"10.1016\/j.fitote.2024.106279","volume":"180","author":"PS Bora","year":"2025","unstructured":"Bora, P. S., Puri, S., Singh, P. P. & Sharma, U. Biochemometric-guided isolation of new Isosteroidal alkaloids from Fritillaria cirrhosa D. Don (Liliaceae, syn. Fritillaria roylei Hook) as acetylcholinesterase inhibitors. Fitoterapia 180, 106279 (2025).","journal-title":"Fitoterapia"},{"issue":"3","key":"44050_CR25","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7150\/ijbs.23247","volume":"14","author":"G Hussain","year":"2018","unstructured":"Hussain, G. et al. Role of plant derived alkaloids and their mechanism in neurodegenerative disorders. Int. J. Biol. Sci. 14(3), 341 (2018).","journal-title":"Int. J. Biol. Sci."},{"issue":"12","key":"44050_CR26","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1080\/1028415X.2025.2531356","volume":"28","author":"D Joshi","year":"2025","unstructured":"Joshi, D. et al. Targeting protein kinases in Parkinson\u2019s disease: The emerging role of phytoconstituents. Nutr. Neurosci. 28(12), 1532\u20131563 (2025).","journal-title":"Nutr. Neurosci."},{"issue":"18","key":"44050_CR27","doi-asserted-by":"publisher","first-page":"5289","DOI":"10.1080\/14786419.2024.2368748","volume":"39","author":"FJ Mohammad Ali","year":"2025","unstructured":"Mohammad Ali, F. J. et al. Molecular docking studies, DFT, and ADMET calculations of some flavonoids and their characteristic structural features involved in inhibition of pro-inflammatory enzymes. Nat. Prod. Res. 39(18), 5289\u20135299 (2025).","journal-title":"Nat. Prod. Res."},{"key":"44050_CR28","doi-asserted-by":"crossref","unstructured":"Jahromi, M. A. F. et al. Virtual screening and computational studies of some naphthoquinones from boraginaceous plants as potential inhibitors of target enzymes involved in leishmaniasis. Mol. Phys. 6, 2e2546025 (2025).","DOI":"10.1080\/00268976.2025.2546025"},{"issue":"03","key":"44050_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1142\/S2737416522500156","volume":"21","author":"M Sherafatizangeneh","year":"2022","unstructured":"Sherafatizangeneh, M., Farshadfar, C., Mojahed, N., Noorbakhsh, A. & Ardalan, N. Blockage of the monoamine oxidase by a natural compound to overcome parkinson\u2019s disease via computational biology. J. Comput. Biophys. Chem. 21(03), 373\u2013387 (2022).","journal-title":"J. Comput. Biophys. Chem."},{"issue":"1","key":"44050_CR30","first-page":"6687572","volume":"2021","author":"AM Kulkarni","year":"2021","unstructured":"Kulkarni, A. M., Rampogu, S. & Lee, K. W. Computer-aided drug discovery identifies alkaloid inhibitors of Parkinson\u2019s disease associated protein, prolyl oligopeptidase. Evidence Based Complement. Altern. Med. 2021(1), 6687572 (2021).","journal-title":"Evidence Based Complement. Altern. Med."},{"issue":"1","key":"44050_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bph.15684","volume":"179","author":"ME Haque","year":"2022","unstructured":"Haque, M. E. et al. Targeting \u03b1-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson\u2019s disease. Br. J. Pharmacol. 179(1), 23\u201345 (2022).","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"44050_CR32","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1527-3458.2007.00020.x","volume":"13","author":"MJ Bonif\u00e1cio","year":"2007","unstructured":"Bonif\u00e1cio, M. J., Palma, P. N., Almeida, L. & Soares-da\u2010Silva, P. Catechol\u2010O\u2010methyltransferase and its inhibitors in Parkinson\u2019s disease. CNS Drug Rev. 13(3), 352\u2013379 (2007).","journal-title":"CNS Drug Rev."},{"issue":"5","key":"44050_CR33","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00702-022-02465-w","volume":"129","author":"WH Jost","year":"2022","unstructured":"Jost, W. H. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson\u2019s disease. J. Neural Transm. 129(5), 723\u2013736 (2022).","journal-title":"J. Neural Transm."},{"key":"44050_CR34","doi-asserted-by":"crossref","unstructured":"Abdel-Magid, A. F. LRRK2 Kinase Inhibitors as Possible Therapy for Parkinson\u2019s Disease and Other Neurodegenerative Disorders 846-847 (ACS, 2019).","DOI":"10.1021\/acsmedchemlett.9b00216"},{"issue":"2","key":"44050_CR35","first-page":"113","volume":"6","author":"L Emami","year":"2020","unstructured":"Emami, L. et al. Molecular docking and antimicrobial evaluation of some novel pyrano [2, 3-C] pyrazole derivatives. Trends Pharm. Sci. Technol. 6(2), 113\u2013120 (2020).","journal-title":"Trends Pharm. Sci. Technol."},{"issue":"1","key":"44050_CR36","first-page":"9984618","volume":"2023","author":"M Rashedinia","year":"2023","unstructured":"Rashedinia, M. et al. Comparison of protective effects of phenolic acids on protein glycation of BSA supported by in vitro and docking studies. Biochem. Res. Int. 2023(1), 9984618 (2023).","journal-title":"Biochem. Res. Int."},{"issue":"25","key":"44050_CR37","doi-asserted-by":"publisher","first-page":"e202201618","DOI":"10.1002\/slct.202201618","volume":"7","author":"Z Faghih","year":"2022","unstructured":"Faghih, Z. et al. Aryloxy Alkyl theophylline derivatives as antifungal agents: Design, synthesis, biological evaluation and computational studies. ChemistrySelect 7(25), e202201618 (2022).","journal-title":"ChemistrySelect"},{"issue":"02","key":"44050_CR38","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1055\/a-2235-8845","volume":"74","author":"A Poustforoosh","year":"2024","unstructured":"Poustforoosh, A., Faramarz, S., Nematollahi, M. H., Mahmoodi, M. & Azadpour, M. Correction: Structure-based drug design for targeting IRE1: An in silico approach for treatment of cancer. Drug Res. 74(02), e1\u2013e1 (2024).","journal-title":"Drug Res."},{"key":"44050_CR39","first-page":"1","volume":"67","author":"A Poustforoosh","year":"2024","unstructured":"Poustforoosh, A. Scaffold Hopping Method for Design and Development of Potential Allosteric AKT Inhibitors. Mol. Biotechnol. 67, 1\u201315 (2024).","journal-title":"Mol. Biotechnol."},{"key":"44050_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11030-025-11114-9","volume":"29","author":"A Poustforoosh","year":"2025","unstructured":"Poustforoosh, A. Optimizing kinase and PARP inhibitor combinations through machine learning and in silico approaches for targeted brain cancer therapy. Mol. Diversity. 29, 1\u201311 (2025).","journal-title":"Mol. Diversity"},{"issue":"9","key":"44050_CR41","doi-asserted-by":"publisher","first-page":"10563","DOI":"10.1016\/j.heliyon.2024.e29850","volume":"10","author":"S Ranjbar","year":"2024","unstructured":"Ranjbar, S. et al. 5-Oxo-dihydropyranopyran derivatives as anti-proliferative agents; synthesis, biological evaluation, molecular docking, MD simulation, DFT, and in-silico pharmacokinetic studies. Heliyon 10(9), 10563 (2024).","journal-title":"Heliyon"},{"key":"44050_CR42","doi-asserted-by":"crossref","unstructured":"Eswaramoorthy, R., Hailekiros, H., Kedir, F. & Endale, M. In silico molecular docking, DFT analysis and ADMET studies of carbazole alkaloid and coumarins from roots of clausena anisata: A potent inhibitor for quorum sensing. Adv. Appl. Bioinf. Chem. 7, 13\u201324 (2021).","DOI":"10.2147\/AABC.S290912"},{"issue":"23","key":"44050_CR43","doi-asserted-by":"publisher","first-page":"10231","DOI":"10.1016\/j.heliyon.2024.e40444","volume":"10","author":"R Sabet","year":"2024","unstructured":"Sabet, R. et al. Pyrazole derivatives as antileishmanial agents: Biological evaluation, molecular docking study, DFT analysis and ADME prediction. Heliyon 10(23), 10231 (2024).","journal-title":"Heliyon"},{"key":"44050_CR44","doi-asserted-by":"publisher","first-page":"107761","DOI":"10.1016\/j.bioorg.2024.107761","volume":"153","author":"G Tataringa","year":"2024","unstructured":"Tataringa, G. et al. Discovery of new molecular hybrid derivatives with coumarin scaffold bearing pyrazole\/oxadiazole moieties: Molecular docking, POM analyses, in silico pharmacokinetics and in vitro antimicrobial evaluation with identification of potent antitumor pharmacophore sites. Bioorg. Chem. 153, 107761 (2024).","journal-title":"Bioorg. Chem."},{"issue":"2","key":"44050_CR45","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1080\/10406638.2022.2032769","volume":"43","author":"A Fatima","year":"2023","unstructured":"Fatima, A. et al. Synthesis, characterization, crystal structure, Hirshfeld surface, electronic excitation, molecular docking, and DFT studies on 2-amino thiophene derivative. Polycycl. Aromat. Compd. 43(2), 1644\u20131675 (2023).","journal-title":"Polycycl. Aromat. Compd."},{"issue":"6","key":"44050_CR46","doi-asserted-by":"publisher","first-page":"102093","DOI":"10.1016\/j.jsps.2024.102093","volume":"32","author":"MA Hossain","year":"2024","unstructured":"Hossain, M. A. et al. In vitro antimicrobial, anticancer evaluation, and in silico studies of mannopyranoside analogs against bacterial and fungal proteins: Acylation leads to improved antimicrobial activity. Saudi Pharm. J. 32(6), 102093 (2024).","journal-title":"Saudi Pharm. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44050-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44050-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44050-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:03:32Z","timestamp":1783037012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44050-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44050"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44050-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20412"}}